Advanced breast cancer: an update and controversies on diagnosis and therapy

被引:10
作者
Nicolini, A
Cupi, A
机构
[1] Univ Pisa, Dept Internal Med, I-56126 Pisa, Italy
[2] Univ Pisa, Dept Reprod & Aging, Pisa, Italy
关键词
advanced breast cancer;
D O I
10.1016/j.biopha.2003.09.003
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This review on advanced breast cancer considered important differences in the actual definition of this condition. Advanced breast cancer includes locally advanced, locoregionally recurrent and metastatic disease, which have different diagnosis, prognosis and therapy; their actual definitions are relatively uncertain. Differently from the common opinion that metastatic breast cancer (MBC) is a very severe incurable disease, recently it has been reported that a small but not irrelevant fraction of MBC patients can be cured or remain in long-term survival with complete remission. The type of metastases of the population studied in these reports was analysed and the authors hypothesised that the particularly high DFS reported mainly was attributable to the high proportion of patients with locoregional metastases only. Furthermore, the options and associations of the drug therapy available for treatment of advanced breast cancer have been reviewed. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
引用
收藏
页码:439 / 446
页数:8
相关论文
共 80 条
[41]   A RANDOMIZED STUDY TO COMPARE THE EFFECT OF THE LUTEINIZING-HORMONE-RELEASING HORMONE (LHRH) ANALOG GOSERELIN WITH OR WITHOUT TAMOXIFEN IN PREMENOPAUSAL AND PERIMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER [J].
JONAT, W ;
KAUFMANN, M ;
BLAMEY, RW ;
HOWELL, A ;
COLLINS, JP ;
COATES, A ;
EIERMANN, W ;
JANICKE, F ;
NJORDENSKOLD, B ;
FORBES, JF ;
KOLVENBAG, GJCM .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (02) :137-142
[42]  
Katz A, 2000, ISRAEL MED ASSOC J, V2, P17
[43]   Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial [J].
Kaufmann, M ;
Bajetta, E ;
Dirix, LY ;
Fein, LE ;
Jones, SE ;
Zilembo, N ;
Dugardyn, JC ;
Nasurdi, C ;
Mennel, RG ;
Cervek, J ;
Fowst, C ;
Polli, A ;
di Salle, E ;
Arkhipov, A ;
Piscitelli, G ;
Miller, LL ;
Massimini, G .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) :1399-1411
[44]   HIGH-DOSE CHEMOTHERAPY WITH REINFUSION OF PURGED AUTOLOGOUS BONE-MARROW FOLLOWING DOSE-INTENSE INDUCTION AS INITIAL THERAPY FOR METASTATIC BREAST-CANCER [J].
KENNEDY, MJ ;
BEVERIDGE, RA ;
ROWLEY, SD ;
GORDON, GB ;
ABELOFF, MD ;
DAVIDSON, NE .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (13) :920-926
[45]  
LABRISH C, 2000, J CLIN ONCOL, V18, P2828
[46]   Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer [J].
Lipton, A ;
Ali, SM ;
Leitzel, K ;
Demers, L ;
Chinchilli, V ;
Engle, L ;
Harvey, HA ;
Brady, C ;
Nalin, CM ;
Dugan, M ;
Carney, W ;
Allard, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1467-1472
[47]   Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial [J].
Lonning, PE ;
Bajetta, E ;
Murray, R ;
Tubiana-Hulin, M ;
Eisenberg, PD ;
Mickiewicz, E ;
Celio, L ;
Pitt, P ;
Mita, M ;
Aaronson, NK ;
Fowst, C ;
Arkhipov, A ;
di Salle, E ;
Polli, A ;
Massimini, G .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) :2234-2244
[48]  
LOTZ JP, 1999, P AN M AM SOC CLIN, V18, pA43
[49]  
MADAN B, 2000, P AN M AM SOC CLIN, V19, pA48
[50]   Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials [J].
Major, P ;
Lortholary, A ;
Hon, J ;
Abdi, E ;
Mills, G ;
Menssen, HD ;
Yunus, F ;
Bell, R ;
Body, J ;
Quebe-Fehling, E ;
Seaman, J .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :558-567